SecBot SecBot
Biotech Drug Report Generated Jul 6, 2026

Veopoz

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and on the market since August 2023
Why 3/10
Veopoz is already FDA-approved (August 18, 2023) and commercialized for an ultra-rare disease. There is no imminent binary catalyst, no pending PDUFA, pivotal readout, or label-expansion decision specific to Veopoz itself within ~12 months. The broader pozelimab+cemdisiran combo program (PNH, gMG) uses the same molecule but follows a separate regulatory path. At a company with $15B+ annual revenue, Veopoz is a tiny contributor, hence score 3 per the approved-drug rubric.
Actionable Insight NEUTRAL

Veopoz is a very small commercial product (~$145-165M total market for CHAPLE disease) within Regeneron's $15B+ revenue base. For REGN investors, watch the pozelimab+cemdisiran combo program (ACCESS-1 for PNH, NIMBLE for gMG), those address much larger markets and are the real value driver for pozelimab as a molecule beyond Veopoz's approved niche.

Price Chart

Loading chart...

Executive Summary

Veopoz (pozelimab-bbfg) is Regeneron's FDA-approved complement C5 inhibitor for the ultra-rare genetic immune disorder CHAPLE disease, the first and only approved treatment for this condition. Approved in August 2023, it was Regeneron's 10th FDA-approved medicine. However, CHAPLE disease affects fewer than 10 patients in the U.S. and fewer than 100 worldwide, making Veopoz a niche product with a total addressable market of ~$145-165M. For Regeneron, a ~$64B market cap company with blockbusters like Dupixent and EYLEA HD generating billions in annual revenue, Veopoz is commercially negligible. The bigger opportunity for the pozelimab molecule lies in the poze-cemdi (pozelimab + cemdisiran) combination program currently in Phase 3 for PNH and gMG, much larger indications, but that follows a separate regulatory path.

How It Works

Veopoz is a lab-made antibody that blocks a specific protein (C5) in the body's complement system, part of the immune system that can become overactive. In CHAPLE disease, the complement system is hyperactivated and attacks the body's own cells, causing leaks in blood vessels and the intestine. By blocking C5, Veopoz stops this destructive cascade. It's given as an initial IV infusion followed by weekly under-the-skin injections.

Trial Status

FDA-approved since August 18, 2023 for CHAPLE disease (CD55-deficient protein-losing enteropathy) in adults and children 1 year+. Approval based on a single-arm Phase 2/3 open-label trial (NCT04209634) showing improved serum albumin, reduced hospitalizations and albumin transfusions. The same molecule (pozelimab) is being studied more broadly in combination with cemdisiran (poze-cemdi) for paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG), Phase 3 ACCESS-1 data presented at ASH 2024 showed superiority over ravulizumab; Phase 3 NIMBLE trial in gMG met primary endpoints (announced August 2025).

The Two-Sided Case

▲ Bull Case4
First and only FDA-approved treatment for CHAPLE disease, effectively no labeled competition (Soliris/Ultomiris used off-label).
As a C5 inhibitor, pozelimab is part of Regeneron's broader complement franchise; the poze-cemdi combination showed superiority over ravulizumab (Ultomiris) in Phase 3 PNH head-to-head data.
Regeneron is a commercial powerhouse with deep rare-disease experience, strong reimbursement, patient-support programs (myRARE), and manufacturing infrastructure already in place.
Ultra-orphan drug pricing supports high per-patient revenue; low patient count means negligible cost exposure for Regeneron's overall P&L.
▼ Bear Case5
Extremely small commercial opportunity, fewer than 100 patients worldwide, so Veopoz contributes immaterially to Regeneron's ~$15B+ annual revenue.
Competing C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab) from Alexion/AstraZeneca are established and used off-label for CHAPLE, creating some competition.
The Phase 2/3 approval was based on a small single-arm open-label study (n=10), no randomized controlled data.
Veopoz carries a Boxed Warning for serious meningococcal infections, requiring vaccination or prophylaxis before and during treatment.
Regeneron's stock has seen analyst downgrades (Citigroup, Leerink in May 2026) and elevated short interest (~54% 14-day avg short ratio), reflecting broader concerns about EYLEA HD competition and pipeline execution.

Upcoming Catalysts

  • No imminent catalyst specific to Veopoz/CHAPLE. The molecule's broader catalyst is the poze-cemdi program: NDA filings for cemdisiran/pozelimab in PNH and gMG (cemdisiran NDA for gMG already submitted with Rare Pediatric Disease Priority Review Voucher).
  • PDUFA target date for Regeneron's garetosmab (FOP) in August 2026, unrelated to Veopoz but a REGN pipeline catalyst.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 13

Hover a chip for the title
1 benzinga.com2 fda.gov3 investor.regeneron.com4 reference.medscape.com5 dailymed.nlm.nih.gov6 fda.gov7 market.us8 hhs.iowa.gov9 thepharmaletter.com10 clinicaltrialsarena.com11 en.wikipedia.org12 sec.gov13 benzinga.com